Frontlight ResearchEarly access
CompletedNo phase
Follow up of IFN Vs DAAs HCV SVR (IFDACS Study)
Key facts
- Who runs it
- Humanity and Health Research Centre
- Where
- China and Japan3 sites in 2 countriesChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 1,210 people enrolled
- Started
- 15 May 2015
- Ended
- 31 Jul 2024
- Type of study
- Observational
- Record updated
- 24 March 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Patients with chronic hepatitis C treated with interferon-based therapy or direct-acting agents (DAAs)-based regimen
- Provide written, informed consent
- Be willing and able to comply with the visit schedule and protocol-mandated procedures
Who cannot take part
- Individuals planning to start a new course of hepatitis C therapy including any investigational drug or device during the course of the follow-up time frame
- History of clinically significant illness or any other major medical disorder that may interfere with follow up, assessments, or compliance with the protocol
- Inability to provide written informed consent
Where is this trial?
It has sites in 2 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
The study is designed to provide long term clinical and virologic follow up in subjects infected with hepatitis C virus (HCV) who received interferon-based therapy or direct-acting antiviral agents (DAAs)-based therapy. This long term follow up study is observational and no treatment is provided for HCV infection.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Long Term Follow-up for Subjects With Chronic Hepatitis C Infection Who Received Interferon-based Therapy or Direct-acting Antiviral Agents (DAAs)-Based Therapy
- Record updated
- 24 March 2025